Open access peer-reviewed chapter - ONLINE FIRST

Anti-Microbial Peptides: The Importance of Structure-Function Analysis in the Design of New AMPs

Written By

Awatef Ouertani, Amor Mosbah and Ameur Cherif

Submitted: July 10th, 2021 Reviewed: August 4th, 2021 Published: February 4th, 2022

DOI: 10.5772/intechopen.99801

IntechOpen
Antimicrobial Peptides Edited by Shymaa Enany

From the Edited Volume

Antimicrobial Peptides [Working Title]

Dr. Shymaa Enany, Dr. Jorge Adrian Masso-Silva and Ph.D. Anna Savitskaya

Chapter metrics overview

47 Chapter Downloads

View Full Metrics

Abstract

In recent years the rapid emergence of drug resistant microorganisms has become a major health problem worldwide. The number of multidrug resistant (MDR) bacteria is in a rapid increase. Therefore, there is an urgent need to develop new antimicrobial agent that is active against MDR. Among the possible candidates, antimicrobial peptides (AMPs) represent a promising alternative. Many AMPs candidates were in clinical development and the Nisin was approved in many food products. Exact mechanism of AMPs action has not been fully elucidated. More comprehensive of the mechanism of action provide a path towards overcoming the toxicity limitation. This chapter is a review that provides an overview of bacterial AMPs named bacteriocin, focusing on their diverse mechanism of action. We develop here the structure–function relationship of many AMPs. A good understanding of AMPS structure–function relationship can helps the scientific in the conception of new active AMPs by the evaluation of the role of each residue and the determination of the essential amino acids for activity. This feature helps the development of the second-generation AMPs with high potential antimicrobial activity and more.

Keywords

  • Multidrug resistant bacteria
  • Antimicrobial peptide
  • mechanism of action
  • peptide synthesis

1. Introduction

The routinely use of antibiotics decreased their efficiency and allowed bacteria to adapt to antibiotics, resulting in the emergence and rapid propagation of resistant bacterial strain [1]. This feature is a serious health and economic problem, leading to increased rates of morbidity and mortality associated with bacterial infections caused by multi resistant bacteria [2] such as Methicillin-Resistant Staphylococcus aureus(MRSA), Vancomycin-Resistant Enterococci (VRE) or MDR [3, 4, 5]. To fight against this health problem, it is imperative to find new alternatives to antibiotics [6]. Several resources were investigated, for their ability to provide antimicrobial agent as well as animals, plants derived compounds and microorganisms [7]. Among natural resources, bacteria are known to be a good producer of antimicrobial agents [8] such as lipopeptides, glycopeptides cyclic peptides and natural peptides named as bacteriocins [9, 10, 11]. The latter are considered as the first line defense of bacteria and allows them to gain a competitive advantage and to thrive in complex ecosystems [11]. Bacteriocins received a great interest as potential antimicrobial agents with high activity against numerous bacterial, fungal, yeast and viral species [12, 13, 14]. Riley et al. have reported that all bacteria are able to produce bacteriocins [15]. A large variety of bacteriocins have been identified, and some bacteria can produce bacteriocins with activity against MDR bacteria [16]. This broad collection of antimicrobial molecules allows many biotechnological, industrial and pharmaceutical applications [17]. Moreover, their toxicity is a limiting factor. Nisin is the only bacteriocin that have been legally approved by the world health organization (WHO) and by the food and drug administration (FDA) for human use as a food preservative, and it has been given a generally-regarded-as-safe (GRAS) designation by the FDA [17]. It is safe for human consumption and is not toxic to animals. Thus, toxicology studies have demonstrated that nisin ingestion does not cause toxic effects to the human body, and LD50 reported was 6950 mg/kg when administered orally [18]. Nisin was shown to be effective against various Gram positive bacteria such as Listeria monocytogenes, Staphylococcusaureus, Bacillus cereus, Bacillus subtilis, Enterococcus faecalis[19]. In adition, Nisin derivatives are more active [17].

Bacteriocins possess a key treats that makes them a good alternative to antibiotics [20]:

  1. They are abundant with large diversity [20, 21].

  2. Various bacteriocins such as nisin [22] have demonstrated distinct mode of action compared to conventional antibiotics.

  3. The use of bacteriocin with narrow spectrum of inhibition preserves the natural healthy microbiota [23].

  4. The long term bacteriocin exposure is safe with no side effects and do not lead to bacterial resistance [24, 25].

The study of bacteriocin structures and amino acids composition helps to understand their detailed mechanism of action. This feature is critical towards the development of bacteriocins as therapeutics and can also be used to prioritize hits in their genome mining studies [26]. Hence a library of synthetic bacteriocin variants served as a tool; to recognize key residues responsible for activity and could continue to inspire the development of new therapeutic agents [27].

Advertisement

2. Bacterial antimicrobial peptides bacteriocins

Bacteriocins are ribosomally synthetised peptides produced by Gram positive, Gram negative bacteria and fungi to kill or inhibit significant pathogenic bacteria [28]. Bacteriocin was discovered for the first time by A. Gratia in 1925 when he was involved in the method of searching for approaches to kill bacteria. The first bacteriocin that inhibited E. coli wasnamed colicin [29]. This powerful biological arm allows microorganisms to compete for resources and space [11]. Bacteriocin can be incorporated in the food products as purified or semi purified form also the producer strain can incorporated. Nisin is exploited in various commercial preparations, such as Nisaplin, Chrisin and DelvoNis. It is commonly used in dairy industries to control clostridia and post-processing contamination from Listeria strains [30]. Furthermore, nisin and further bacteriocins have been shown to inhibit several pathogens in many food matrixes. Many studies have demonstrated the anti-biofilm properties of nisin and the capacity to act synergistically in combination with conventional therapeutic drugs [31]. In addition, nisin could stimulate the adaptive immune response with an immunomodulatory function. Also, nisin can control the growth of tumors and exhibit selective cytotoxicity towards cancer cells [32]. Bacteriocins have also been identified as promising next generation antibiotics to combat MDR pathogens [33].

2.1 Classification

During the years of discovery, numerous approaches have been taken to classify bacteriocins into a number of groups. This includes the nature of the producing strains, the methods by which these molecules are produced, common resistance mechanisms and the peptides mechanism of actions [34]. The most useful classification established by Claenhamer et al. (1993) subdivides bacteriocin into four classes [35] as follow:

ClassI: small bacteriocin with a molecular weight less than 5 kDa, heat stable and harbor non-standard amino acids such as lanthionine, β methyllanthionine, dehydrobulyrine, dehydroalanine and labyrinthine [36].Class I is subdivided into:

  1. class Ia (lantibiotics): consists of flexible, elongated, positively charged, and hydrophobic peptides associated with a pore formation in bacterial membranes. Nisin is the most representative bacteriocin of this group.

  2. class Ib (labyrinthopeptins): it regroups globular and inflexible bacteriocins that are negatively charged or with no net charge. These bacteriocins can inhibit catalytic enzymes crucial for the proliferation of susceptible bacteria [37].

  3. class Ic (sanctibiotics) are sulfur-to-α-carbon-containing peptides [38]. Nisin is the most studied class I bacteriocin [39].

ClassII: Class II bacteriocin regroups peptides with a molecular weight less than 10 kDa, heat stable and with no modified amino acids. This class is subdivided into four sub-classes. Class IIa also named pediocin like bacteriocins [40]. It regroups bacteriocin typically comprised of 25–28 AA with a conserved amino acid sequence YGNGV on their N-terminal domains [41]. Class IIb or two peptides bacteriocin. This class regroups two different peptides, both are essential for the antimicrobial activity [37]. Class IIc: circular bacteriocins produced by Gram-positive bacteria represent a diverse class of antimicrobial peptides that are more stable compared to linear bacteriocins [42]. Class IId: linear non-pediocin-like one-peptide bacteriocins [43].

Class III: the large and heat labile bacteriocins. Colicin is one of the well-characterized Class III bacteriocin They have a bacteriolytic (IIIa) or nonlytic mechanism of action (class IIIb) [44].

Class IV: this class regroups complex protein associated with one or more chemical moieties either lipid or carbohydrate [45].

2.2 Biosynthesis

Bacteriocins are primary metabolites with simpler biosynthetic machinery [46]. Bacteriocin coding genes are generally in operon clusters with the minimum genetic machinery, composed of the structural gene and the associated immunity. The clusters harbored in the genome, plasmid or other mobile genetic elements [47]. Bacteriocins are synthesized as inactive precursor peptides composed of an N-terminal leader peptide close to the C-terminal pro-peptide. The leader peptide serves as a recognition site for the biosynthetic enzymes implicated in the maturation process and its transport outside of the producer strain [2]. Bacteriocins are transported and cleaved to generate the mature form through enzymatic processes [48]. Recently, various leaderless bacteriocin has been reported [49, 50] with no common biosynthesis and regulation mechanism [51]. Leaderless bacteriocins do not undergo post translational modification and become active after [51]. Coelho et al. (2016) have reported that a complex mechanism involving a protein with a helix-turn-helix (HTH) AurR, an alternative transcription factor σB, and a phage regulator ϕ11, regulates the production of aureocin A70 [52]. An ABC-type multi-drug resistance transporter protein, LmrB, has been reported to be implicated in secretion and immunity of the LsbB, leaderless bacteriocin [53].

2.3 Mode of action

Usually, Gram-negative bacteria are naturally resistant to the bacteriocins, due to their outer membrane, which acts as an effective barrier [54, 55]. Microcin B17 (MccB17) is an antibacterial peptide produced by strains of Escherichia coliharboring the plasmid-borne mccB17 operon [56]. This bacteriocin passes through the outer membrane via the porin OmpF and is transferred across the inner membrane in a manner that is dependent on the inner-membrane peptide transporter SbmA. The bacteriocin then acts by inhibiting DNA gyrase-mediated DNA supercoiling, thus interfering with DNA replication [20].

The bacteriocin MccJ25 is recognized by the iron siderophore receptor FhuA at the outer membrane and requires TonB and SbmA at the inner membrane to go through the cell. After entering the cell, MccJ25 block the secondary channel of RNA polymerase resulting on the transcription inhibition [57]. MccC7-C51, passes through the inner layer of the E. colicell wall via the YejABEF transporter [58], after which the bacteriocin is processed by one of the many broad-specificity cytoplasmic aminopeptidases of the bacterium [59] to generate a modified aspartyl-adenylate. This, in turn, inhibits aspartyl-tRNA synthetase, thus blocking mRNA synthesis (Figure 1) [20].

Figure 1.

Illustration of mechanism of action of representative bacteriocins that inhibit gram-positive (a) and gram-negative bacteria [20].

The general cationic nature of bacteriocins plays a key role in their initial interaction with the cell membrane of the target strains. The negative charge of bacterial cell membranes and the positive charge of bacteriocin generate an electrostatic interaction between them, thus facilitating the approach of the molecules to the membranes [60]. Lantibiotic such as nisin have dual killing mechanism that require its interaction with lipid II receptor leading to i) pore forming that induces the dissipation of the membrane potential and the efflux of small metabolites such as ions, amino acids, nucleotides and other cytoplasmic solutes, resulting in the execution of all biosynthetic processes and the cell death. ii) prevention of peptidoglycan, the main component of the bacterial cell wall, synthesis, causing cell death [61]. Whereas, Members of class IIa bacteriocins have been shown to bind to mannose phosphotransferase system (Man-PTS) proteins, the sugar-uptake system of target bacteria, to exhibit their antimicrobial activity [62]. Their anti listerial activity is due to the conserved N-terminal YGNGV motif, while the less conserved C-terminal domain is responsible for their antimicrobial activity against other strains [41]. Circular bacteriocin such as enterocin AS-48, gassericin A, subtilosin A, and carnocyclin do not require a receptor molecule for their activity. Their basic amino acid residues patch on the surface of their compact hydrophobic globular structure was responsible for the electrostatic interaction between the bacteriocin and the surface membrane of the target cell [63]. However, garvicin ML, a new member of circular bacteriocins, exhibits its activity through binding to a maltose ABC-transporter protein as a target receptor of garvicin ML, which facilitates the efflux of intracellular solutes resulting to the cell death [42].

Leaderless bacteriocins have been shown to not involve a receptor molecule to exhibit their antimicrobial activity [51]. Fujita et al. [64] characterized the mode of action of Lacticin Q, leaderless bacteriocins produced by L. lactis QU5. It demonstrates antimicrobial activity against various Gram-positive bacteria such as Bacillus sp., Lactobacillus sp., Enterococcus sp., Lactococcus sp., and Staphylococcus aureus[64]. Lacticin Q has been shown to form toroidal pore (HTP) causing depletion of intracellular components such as proteins, ions and ATP, leading to cell death. The HTP formation mechanism initiates with the electrostatic interaction of the cationic lacticin Q and the negatively charged membranes. These binding results in the formation of HTPs associated with lipid flip-flop [51]. In addition, the leaderless aureocin A53 produced by S. aureusA53 was shown to permeate the membranes of the bacteria without forming pores [65]. It demonstrates stronger interaction with neutral membrane rather than negatively charged lipids. Studies on the leaderless bacteriocin, LsbB, isolated from L. lactis subsp. lactisBGMN1–5, shed light on a zinc-dependent membrane metallopeptidase, YvjB, as its receptor molecule [66]. The C-terminal end of LsbB harbors the receptor binding domain [67] that interacts with the highly conserved Tyr356 and Ala353 residues located at the transmembrane domain of YvjB [68] (Figures 1 and 2).

Figure 2.

Illustration of different mechanism of action of three classes’ bacteriocins [37].

2.4 Structural analysis: amino acids and activity

NMR resolution structure of circular bacteriocins such as; enterocin AS-48, carnocyclin A, enterocin NKR 5-3B and acidocin B demonstrates a conserved structural motif consisting of four to five α-helices surrounding a hydrophobic core, with the C-terminus and N-terminus ligation occurring within an helix secondary structure [63, 69, 70, 71, 72] (Figure 3). Various studies suggested that the circularization is not essential for antimicrobial activity but more important for stabilization of the three-dimensional structure of the bacteriocin [73, 74, 75, 76]. Jimenez et al. (2005) demonstrated that a fragment of enterocin AS-48 harboring the cationic putative membrane interacting region exhibited competitive membrane binding with no antibacterial activity. This result suggests that the cationic surface patches are involved in an initial electrostatic interaction between the peptide and the negatively charged phospholipids bilayer of target cell membrane. Furthermore, other physicochemical properties of the bacteriocins may be required for antimicrobial action [42, 51, 77]. Additionally, mutation of aromatic residues in AS-48 reduced activity which shed light on the role of aromatic amino acids on antimicrobial activity.

Figure 3.

Crystal structure of AS-48 (PDB 1O82) [26].

Furthermore, the crystal structure and site directed mutagenesis of plantacyclin B21AG reveals that Phe8, Trp45 and Lys19 are essential for antimicrobial activity and a significant reduction in activity was observed with Alanine substitution mutagenesis supporting the notion of a similar role of these residues [78] (Figure 4). Moreover, many Trp rich AMPs (TrAMPs) has shown interesting antifungal activity such as synthetic peptides PW2 [79], PAF2 [80] and PEP6[81]. Also, Blondelle et al. have synthesized Combi-1, Combi-2 and Cyclo-Combi, three TrAMPs with high antimicrobial activity against E.coli, S.aureus, S.sanguis and C.albicans[82]. Trp residues are always associated with Arg residues which have a positively charged guanidium group located at the end of the side chain. This group ensures i) the attraction of the TrAMPs to target membranes by forming hydrogen bonds with the negatively charged membrane component. ii) Electrostatic and H-bonding with anionic and polar molecule resulting on the cell penetrating peptides. These distinctive properties are crucial for the highly activity of the Arg and Trp –rich peptides even at very short peptide lengths [83].

Figure 4.

Crystal structure of B21AG showing amino acids essential for activity [78].

Various studies have illuminated the picture of structural and functional relationships in nisin. Thus, the specific mutation shed light on the key regions essential for antimicrobial activity. N-terminal was found to be crucial for nisin binding to the lipidII pyrophosphate region [84]. Therefore, the first two residues IL1 and Dhb2 associated with N-ter lanthhionine ring A and methyl lanthionine ringB forms a pocket that encloses the lipidII. This interaction is ensured by the hydrogen binding between the pyrophosphate group of lipidII and the backbone amides [26] (Figure 5). Wiedemann et al. have demonstrated that C-terminal region is crucial for binding to membrane with a negative surface charge. However, aa33 and aa34 did not play any role in vivo activity [85]. Also, the substitution of Val32 by Lys or Glu residue results on the drastic decrease of activity associated with a significant reduction on K+ release. This feature demonstrated that the presence of a charged residue in the central segment of the molecule is not tolerable and affect the pore forming process [85]. The C and N-terminal regions are separated by a few residues that proceed as a flexible pivot around which the C-terminal of nisin can rotate and insert vertically into the phospholipids bilayer [26].

Figure 5.

NMR structure (PDB: 1WCO) of nisin bound to a lipid II analog. Nisin is shown as a space-filling model and the lipid II analog is shown as sticks. The N-terminal (methyl)lanthionine rings (space-filling tan) of nisin envelop the pyrophosphate moiety (magenta and cyan sticks) of lipid II [26].

Subtilosin A a bacteriocin produced by B.subtiliswas also characterized. It is composed of three cyclic segments. The intramolecular linkages are ensured by three thioether bridges connecting C4 with F31, C7 with T28, and C13 with F22, while an amide bond between N1 and G35 links the N- and C-terminus of the peptide (Figure 6). This feature contributes to the semi-rigid, cyclic nature of subtilosin A [86, 87, 88]. Subtilosin A contain many hydrophobic residues, but there are also three acidic residues, two Aspartate and one glutamate, that are localized on the loop end of the folded peptide and a basic residue,Lysine, present on the opposite end. This separation of charge confers a net anionic (−2). Thus, like bacteriocin, the model proposed for binding engages insertion of the loop-distal end of subtilosin A into the lipid bilayer first [88]. This end harbors the single basic residue, K2, which may interact with the negatively charged phosphate headgroup and a large, hydrophobic tryptophan residue, W34, which may disturb the lipid bilayer [88]. The insertion of subtilosin A causes an ATP efflux and a reduction of the transmembrane ion gradient [89].

Figure 6.

The crystal structure of subtilosin A (PDB:1PXQ) illustrates a rigid hairpin-like structure. Acidic (D16, D21, E23) and basic (K2) amino acids are localized at different ends of the folded peptide. Residues participating in thioether linkages are shown as gold sticks [26].

Advertisement

3. Conclusion

In recent years, the increased number of MDR pathogens has become a serious problem, and developing a new generation of antimicrobial agents is becoming urgent.

Increased interest has been shown in bacteriocin, AMPs produced by bacteria, particularly the one produced by lactic acid bacteria (LAB) [90]. Numerous bacteriocins have been shown to be effective against many pathogenic bacteria [24]; however, Nisin is the only bacteriocin legally approved by the WHO and by FDA for use in the food, medicine and veterinary industry [91]. Many, derivatives of nisin have been developed and used in various applications.

Bacteriocins are diverse with different mechanism of action. A deepest comprehensive of mechanism of action and the identification of key amino acids and receptor crucial for activity helps to understand the detailed mechanism of action. This feature leads to the development of new antibiotics effective against MDR bacteria and to solve the problem of bacterial resistance.

To address this issue, in this chapter, we have compiled available data to shed light on the structural function relationship of various bacteriocins.

References

  1. 1. Gould IM (2009). Antibiotic resistance: The perfect storm. Int J Antimicrob Agents 34:S2–S5
  2. 2. Simons A, Alhanout K, Duval RE (2020). Bacteriocins, Antimicrobial Peptides from Bacterial Origin: Overview of Their Biology and Their Impact against Multidrug-Resistant Bacteria. Microorganisms 8(5):639
  3. 3. Xia J, Gao J, Kokudo N, Hasegawa K, Tang W (2013). Methicillin-resistantStaphylococcus aureusantibiotic resistance and virulence. Biosci. Trends 7:113-121
  4. 4. Giamarellou H, Poulakou G (2009). Multidrug-Resistant Gram-Negative Infections. Drugs 69:1879-1901
  5. 5. Calfee DP (2012). Methicillin-resistantStaphylococcus aureusand vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Infect Dis 25:385
  6. 6. Duval RE, Grare M, Demoré B (2019). Fight Against Antimicrobial Resistance: We Always Need New Antibacterials but for Right Bacteria. Molecules. 24(17):3152
  7. 7. Mbaveng AT, Sandjo LP, Tankeo SB, Ndifor AR, Pantaleon A, Nagdjui BT, Kuete V (2015). Antibacterial activity of nineteen selected natural products against multi-drug resistant Gram-negative phenotypes Springer plus 30 (4):823
  8. 8. Abriouel H, Franz CM, Ben Omar N, Galvez A (2011). Diversity and application of Bacillus bacteriocins. FEMS Microbiol Rev 35:201-232
  9. 9. Kleinkauf H, von Döhren H. Review Nonribosomal biosynthesis of peptide antibiotics. In: Christen P, Hofmann E, editors. EJB Reviews 1990. Springer; Berlin/Heidelberg, Germany: 1991. pp. 151-165. European Journal of Biochemistry
  10. 10. Saadouli I, Zendah El Euch I, Trabelsi E, Mosbah A, Redissi A, Ferjani R, Fhoula I, Cherif A, Sabatier JM, Sewald N, Ouzari HI (2020). Isolation, Characterization and Chemical Synthesis of Large Spectrum Antimicrobial Cyclic Dipeptide (l-leu-l-pro) fromStreptomyces misionensisV16R3Y1 Bacteria Extracts. A Novel 1H NMR Metabolomic Approach. Antibiotics (Basel). 21;9(5):270
  11. 11. Ouertani A, Chaabouni I, Mosbah A, Long J, Barakat M, Mansuelle P, Mghirbi O, Najjari A, Ouzari H-I, Masmoudi AS, Maresca M, Ortet P, Gigmes D, Mabrouk K and Cherif A (2018) Two New Secreted Proteases Generate a Casein-Derived Antimicrobial Peptide inBacillus cereusFood Born Isolate Leading to Bacterial Competition in Milk Front. Microbiol. 9:1148
  12. 12. Chi H, Holo H (2018). Synergistic Antimicrobial Activity Between the Broad Spectrum Bacteriocin Garvicin KS and Nisin, Farnesol and Polymyxin B Against Gram-Positive and Gram-Negative Bacteria Curr Microbiol 75(3):272-277
  13. 13. Smaoui S, Elleuch L, Bejar W, Karray-Rebai I, Ayadi I, Jaouadi B, Mathieu F, Chouayekh H, Bejar S, Mellouli L (2010). Inhibition of fungi and gram-negative bacteria by bacteriocin BacTN635 produced byLactobacillus plantarumsp. TN635 Appl Biochem Biotechnol 162(4):1132-1146
  14. 14. Sharma A, Srivastava S (2014). Anti-Candida activity of two-peptide bacteriocins, plantaricins (Pln E/F and J/K) and their mode of action Fungal Biol 118(2):264-275
  15. 15. Riley M A, Wertz J E (2002). Bacteriocins: evolution, ecology, and application. Annu Rev Microbiol 56: 117-137
  16. 16. El-Gendy, A.O., Brede, D.A., Essam, T.M. et al (2021). Purification and characterization of bacteriocins-like inhibitory substances from food isolated Enterococcus faecalis OS13 with activity against nosocomial enterococci Sci Rep 11, 3795
  17. 17. Kamarajan P, Hayami T, Matte B, Liu Y, Danciu T, Ramamoorthy A, et al. (2015). Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival. PLoS ONE 10(7): e0131008
  18. 18. Jozala AF, Novaes L.CdL, Júnior AP. (Nisin 2015). In Concepts, Compounds and the Alternatives of Antibacterials IntechOpen: London, UK: 103-119
  19. 19. Sukrita PP, Parichat P, Pongsak R 2015. Nisin: production and mechanism of antimicrobial action. Int J Cur Res Rev 7 (2): 47-53
  20. 20. Cotter PD, Ross RP, Hill C (2013). Bacteriocins - a viable alternative to antibiotics? Nat Rev Microbiol 11(2):95-105
  21. 21. Yang SC, Lin CH, Sung CT, Fang JY (2014). Antibacterial activities of bacteriocins: application in foods and pharmaceuticals Front Microbiol 26(5):241
  22. 22. Campion A, Casey PG, Field D et al (2013). In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice BMC Microbiol 13( 23)
  23. 23. Francino MP (2016). Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances Front Microbiol 12(6):1543
  24. 24. Soltani S, Hammami R, Cotter PD, Rebuffat S, Ben Said L, Gaudreau H, Bédard F, Biron E, Drider D, Fliss I(2021). Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations. FEMS microbial Rev45(1): fuaa039
  25. 25. Hagiwara A, Imai N, Nakashima H, Toda Y, Kawabe M, Furukawa F, Delves-Broughton J, Yasuhara K, Hayashi SM (2010). A 90-day oral toxicity study of nisin A, an anti-microbial peptide derived from Lactococcus lactis subsp. lactis, in F344 rats Food Chem Toxicol 48(8-9):2421-2428
  26. 26. Cao L, Turq D, James Link A (2021). Mechanisms of action of ribosomally synthesized and posttranslationally modified peptides (RiPPs) J Ind Microbiol. Biotechnol 48
  27. 27. O’ Connor PM, O’ Shea EF, Cotter PD et al (2018). The potency of the broad spectrum bacteriocin, bactofencin A, against staphylococci is highly dependent on primary structure, N-terminal charge and disulphide formation Sci Rep 8:118-133
  28. 28. Benítez-Chao DF, León-Buitimea A, Lerma-Escalera JA , Morones-Ramírez JR (2021). Bacteriocins: An Overview of Antimicrobial, Toxicity, and Biosafety Assessment by in vivo Models Front Microbiol 12:630-695
  29. 29. Gratia A (1925). Sur un remarquable example d'antagonisme entre deux souches de colibacille. Comput Rend Soc Biol 93: 1040-1042
  30. 30. Thomas LV, Delves-Broughton J (2001). New Advances in the Application of the Food Preservative Nisin Res Adv Food Sci 2: 11-22
  31. 31. Shin JM, Gwak JW, Kamarajan P, Fenno JC, Rickard AH, Kapila YL (2016). Biomedical applications of nisin. J Appl Microbiol 120(6):1449-1465
  32. 32. Kaur S, Kaur S (2015). Bacteriocins as Potential Anticancer Agents. Front Pharmacol 6:272
  33. 33. Perez R H, Zendo T, Sonomoto K (2014). Novel bacteriocins from lactic acid bacteria (LAB): various structures and applications Microb Cell Fact 13 ( 1)
  34. 34. Chikindas ML, Weeks R, Drider D, Chistyakov VA, Dicks LM (2018). Functions and emerging applications of bacteriocins Curr Opin Biotechnol 49:23-28
  35. 35. Klaenhammer TR(1993). Genetics of bacteriocins produced by lactic acid bacteria FEMS Microbiol Rev 12: 39-86
  36. 36. Parada JL, Caron CR, Medeiros ABP, Soccol CR (2007). Bacteriocins from lactic acid bacteria: purification, properties and use as biopreservatives, Braz Arch Biol Technol 50: 521-525
  37. 37. Hernández-González JC, Martínez-Tapia A, Lazcano-Hernández G, García-Pérez BE, Castrejón-Jiménez NS (2021). Bacteriocins from Lactic Acid Bacteria. A Powerful Alternative as Antimicrobials, Probiotics, and Immunomodulators in Veterinary Medicine Animals 11: 979
  38. 38. Alvarez-Sieiro P, Montalbán-López M, Mu D, Kuipers OP (2016). Bacteriocins of Lactic Acid Bacteria: Extending the Family Appl MicrobiolBiotechnol. 100: 2939-2951
  39. 39. Le Lay C, Dridi L, Bergeron M.G, Ouellette M, Fliss I (2016). Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J Med Microbiol 65: 169-175
  40. 40. Bédard F, Biron E (2018). Recent Progress in the Chemical Synthesis of Class II and S-Glycosylated Bacteriocins Front Microbiol 9, 1048
  41. 41. Fimland G, Johnsen L, Dalhus B, Nissen-Meyer J (2005). Pediocin-like Antimicrobial Peptides (Class IIa Bacteriocins) and Their Immunity Proteins: Biosynthesis, Structure, and Mode of Action J Pept Sci 11: 688-696
  42. 42. Gabrielsen C, Brede D A, Nes I F, Diep D B (2014). Circular bacteriocins: biosynthesis and mode of action Appl Environ Microbiol 80: 6854-6862
  43. 43. Angelopoulou A, Warda AK, O’Connor PM, Stockdale SR, Shkoporov AN, Field D, Draper LA, Stanton C, Hill C and Ross RP (2020). Diverse Bacteriocins Produced by Strains From the Human Milk Microbiota Front Microbiol 11:788
  44. 44. Sun Z, Wang X, Zhang X, Wu H, Zou Y, Li P, Sun C, Xu W, Liu F, Wang D. Class III bacteriocin Helveticin-M causes sublethal damage on target cells through impairment of cell wall and membrane (2018) J Ind Microbiol Biotechnol 45(3):213-227
  45. 45. Mduduzi Paul Mokoena (2017). Lactic Acid Bacteria and Their Bacteriocins: Classification, Biosynthesis and Applications against Uropathogens: A Mini-Review Molecules 22(8): 1255
  46. 46. Pham JV, Yilma MA, Feliz A, Majid MT, Maffetone N, Walker JR, Kim E, Cho HJ, Reynolds JM, Song MC, Park SR and Yoon YJ (2019) A Review of the Microbial Production of Bioactive Natural Products and Biologics Front Microbiol 10:1404
  47. 47. Azevedo AC, Bento CB, Ruiz JC, Queiroz MV, Mantovani HC (2015). Distribution and Genetic Diversity of Bacteriocin Gene Clusters in Rumen Microbial Genomes Appl Environ Microbiol 81(20):7290-7304
  48. 48. Todorov SD (2009). Bacteriocins fromLactobacillus plantarum- production, genetic organization and mode of action: produção, organização genética e modo de ação Braz J Microbiol 40(2):209-221
  49. 49. Iwatani S, Zendo T, Sonomoto K (2011). Class IId or Linear and Non-Pediocin-Like Bacteriocins Prokaryotic Antimicrob Peptides 237-252
  50. 50. Masuda Y et al (2011). Identifcation and characterization of leucocyclicin Q, a novel cyclic bacteriocin produced byLeuconostoc mesenteroidesTK41401 Appl Environ Microbiol 77: 8164-8170
  51. 51. Perez RH, Zendo T , Sonomoto K (2018). Circular and Leaderless Bacteriocins: Biosynthesis, Mode of Action, Applications, and Prospects. Front Microbiol 9:2085
  52. 52. Coelho ML, Fleming LR, Bastos Mdo C(2016). Insights into aureocin A70 regulation: participation of regulator AurR, alternative transcription factor σ(B) and phage ϕ11 regulator cI Res Microbiol 167(2):90-102
  53. 53. Gajic O, Buist G, Kojic M, Topisirovic L, Kuipers OP, Kok J. (2003). Novel mechanism of bacteriocin secretion and immunity carried out by lactococcal multidrug resistance proteins J Biol Chem 278: 34291-34298
  54. 54. Prudêncio CV, Dos Santos MT, Vanetti MC(2015). Strategies for the use of bacteriocins in Gram-negative bacteria: relevance in food microbiology J Food Sci Technol 52(9):5408-5417
  55. 55. Gyawali R, Ibrahim SA. Natural products as antimicrobial agents. Food Control. 2014;46:412-429. doi: 10.1016/j.foodcont.2014.05.047
  56. 56. Collin f, Maxwell A (2019). The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents J Mol Biol 431(18):3400-3426
  57. 57. Vincent P A, Morero RD (2009). The structure and biological aspects of peptide antibiotic microcin J25, Curr. Med. Chem. 16: 538-549
  58. 58. Novikova M. et al (2007). The Escherichia coli Yej transporter is required for the uptake of translation inhibitor microcin C. J. Bacteriol 189:8361-8365
  59. 59. Kazakov T et al (2008). Escherichia coli peptidase A, B, or N can process translation inhibitor microcin C J Bacteriol 190: 2607-2610
  60. 60. Rodney H. Perez, Maria Teresa M P, Francisco B E (2015). Bacteriocins from Lactic Acid Bacteria: A Review of Biosynthesis, Mode of Action, Fermentative Production, Uses, and Prospects Phil Sci Tech 08(2): 61
  61. 61. McAuliffe RO, Ross P, Hill C, Lantibiotics: structure, biosynthesis and mode of action (2001), FEMS Microbiology Reviews 25 (3): 285-308
  62. 62. Tymoszewska A, Diep DB, Wirtek P et al (2017). The Non-Lantibiotic Bacteriocin Garvicin Q Targets Man-PTS in a Broad Spectrum of Sensitive Bacterial Genera Sci Rep 7: 8359
  63. 63. Van Belkum M J, Martin-Visscher L A Vederas J C(2011). Structure and genetics of circular bacteriocins. Trends Microbiol 19:411-418
  64. 64. Fujita K, IchimasaS, Zendo T, Koga S, Yoneyama F, Nakayama J et al (2007). Structural analysis and characterization of lacticin Q, a novel bacteriocin belonging to a new family of unmodified bacteriocins of Grampositive bacteria Appl Environ Microbiol 73: 2871-2877
  65. 65. Netz D J A, Bastos M, do C, de F, Sahl H G (2002). Mode of action of the antimicrobial peptide aureocin A53 fromStaphylococcus aureusAppl Environ Microbiol 68: 5274-5280
  66. 66. Uzelac G, Kojic M, Lozo J, Aleksandrzak-Piekarczyk T, Gabrielsen C, Kristensen T et al. (2013). A Zn-Dependent metallopeptidase is responsible for sensitivity to LsbB, a class ii leaderless bacteriocin ofLactococcus lactissubsp. lactis BGMN1-5 J Bacteriol195: 5614-5621
  67. 67. Ovchinnikov K V, Kristiansen P E, Uzelac G, Topisirovic L, Kojic M, NissenMeyer J et al (2014). Defining the structure and receptor binding domain of the leaderless bacteriocin LsbB J BiolChem 289: 23838-23845
  68. 68. Miljkovic M, Uzelac G, Mirkovic N, Devescovi G, Diep D B, Venturi V et al. (2016). LsbB bacteriocin interacts with the third transmembrane domain of the YvjB receptor Appl Environ Microbiol 82: 5364-5374
  69. 69. Himeno K et al (2015). Identifcation, characterization, and three-dimensional structure of the novel circular bacteriocin, enterocin NKR-5-3B, fromEnterococcus faeciumBiochemistry 54:4863-4876
  70. 70. Acedo J Z et al (2015). Solution structure of acidocin B, a circular bacteriocin produced byLactobacillus acidophilusM46 Appl Environ Microbiol 81:2910-2918
  71. 71. Sánchez-Barrena MJ, Martínez-Ripoll M, Gálvez A, et al (2003). Structure of bacteriocin AS-48: From soluble state to membrane bound state J Mol Biol 334:541-549
  72. 72. Martin-Visscher L A, Gong X, Duszyk M, Vederas J C (2009). Te three-dimensional structure of carnocyclin A reveals that many circular bacteriocins share a common structural motif J Biol Chem 284: 28674-28681
  73. 73. Montalbán-López M et al (2008). Characterization of linear forms of the circular enterocin AS-48 obtained by limited proteolysis FEBS Lett 582: 3237-3242
  74. 74. Sánchez-Hidalgo M et al (2011). AS-48 bacteriocin: close to perfection. Cell Mol Life Sci 68: 2845-2857
  75. 75. Cobos E et al (2001). AS-48: a circular protein with an extremely stable globular structure. FEBS Lett 505: 379-382
  76. 76. Cobos E S et al (2002). The denaturation of circular enterocin AS-48 by urea and guanidinium hydrochloride Biochim Biophys Acta Proteins Proteom 1598: 98-107
  77. 77. Jiménez M A, Barrachi-Saccilotto A C, Valdivia E, Maqueda M, Rico M (2004). Design, NMR characterization and activity of a 21-residue peptide fragment of bacteriocin AS-48 containing its putative membrane interacting region J of Pep Sci 11(1): 29-36
  78. 78. Gor MC, Vezina B, McMahon RM et al (2020). Crystal structure and site-directed mutagenesis of circular bacteriocin plantacyclin B21AG reveals cationic and aromatic residues important for antimicrobial activity Sci Rep 10: 173-98
  79. 79. Da Silva A, Kawazoe U, Freitas FFT, Gatti MSV, Dolder H, Schumacher RI, Juliano MA, da Silva MJ, Leite A, Avian (2002). Anticoccidial activity of a novel membrane-interactive peptide selected from phage display libraries Mol Biochem Parasitol 120: 53-60
  80. 80. López-García B Pérez-Payá E Marcos JF (2002). Identification of novel hexapeptides bioactive against phytopathogenic fungi through screening of a synthetic peptide combinatorial library Appl Environ Microbiol 68: 2453-2460
  81. 81. Reed JD, Edwards DL, Gonzalez CF (1997). Synthetic peptide combinatorial libraries: A method for the identification of bioactive peptides against phytopathogenic fungiMolPlant-Microbe Interact 10: 537-549
  82. 82. Blondelle SE, Pérez-Payá E, Houghten RA (1996). Synthetic combinatorial libraries: Novel discovery strategy for identification of antimicrobial agents Antimicrob Agents Chemother 40: 1067-1071
  83. 83. Awdhesh KM, Jaehyuk C, Eunpyo M, Kwang H B (2018). Tryptophan and Proline rich antimicrobial peptides Molecules 23:815
  84. 84. Hsu STD, Breukink E, Tischenko E, et al (2004). The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics Nat Struct Mol Biol 11:963-967
  85. 85. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, SahlHG. (2001). Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity J Biol Chem 276: 1772-1779
  86. 86. Marx R, Stein T, Entian KD, Glaser SJ (2001). Structure of the Bacillus subtilis peptide antibiotic subtilosin A determined by 1H-NMR and matrix assisted laser desorption/ionization time-of-flight mass spectrometry J Protein Chem 20:501-506
  87. 87. Kawulka KE, Sprules T, Diaper CM, et al (2004). Structure of Subtilosin A, A Cyclic Antimicrobial Peptide fromBacillus subtiliswith Unusual Sulfur to α-Carbon Cross-Links: Formation and Reduction of α-Thio-α-Amino Acid Derivatives. Biochemistry 43:3385– 3395
  88. 88. Thennarasu S, Lee DK, Poon A, Kawulka KE, Vederas JC, Ramamoorthy A. (2005). Membrane permeabilization, orientation, and antimicrobial mechanism of subtilosin A Chem Phys Lipids 137(1-2): 38-51
  89. 89. Noll KS, Sinko PJ, Chikindas ML, et al (2011). Elucidation of the Molecular Mechanisms of Action of the Natural Antimicrobial Peptide Subtilosin Against the Bacterial Vaginosis associated PathogenGardnerella vaginalisProbiotics Antimicro 3:41-47
  90. 90. Vieco-Saiz N, Belguesmia Y, Raspoet R, Auclair E, Gancel F, Kempf I and Drider D (2019). Benefits and Inputs From Lactic Acid Bacteria and Their Bacteriocins as Alternatives to Antibiotic Growth Promoters During Food-Animal Production Front Microbiol 10:57
  91. 91. Khan I, Oh DH (2016). Integration of nisin into nanoparticles for application in foods Innov Food Sci Emerg Technol 34: 376-384

Written By

Awatef Ouertani, Amor Mosbah and Ameur Cherif

Submitted: July 10th, 2021 Reviewed: August 4th, 2021 Published: February 4th, 2022